John Oyler, Co-Founder, Chairman, and CEO at BeOne Medicines, shared on LinkedIn:
“‘Cancer has no borders, and neither do we.’
That belief has shaped how we built BeOne from the beginning. Because cancer is a global challenge. The science needed to address it is global too. So rather than treating ‘global’ as something you become over time, we built it into our company from the start, bringing together talented researchers, clinicians and colleagues across countries and continents, and building the capabilities to discover, develop and deliver medicines at global scale.
I recently had the opportunity to discuss this journey on Cambridge Associates’ Unseen Upside podcast, including why we invested in building our own global development ‘superhighway’ and what I’ve learned about the power of scientific collaboration across borders.
I’m grateful to our colleagues around the world who have turned an ambitious idea into a truly global oncology company, working every day to change what’s possible for people living with cancer.
There is much more work ahead, and that’s what makes the future so exciting.
I hope you’ll listen to the conversation.”
Listen to Cancer Without Borders: Backing the Best Science
About Unseen Upside
The Unseen Upside podcast, produced by Cambridge Associates, features conversations with business leaders, investors, entrepreneurs and innovators about how investments and new ideas can create meaningful impact beyond financial returns. Its discussions cover areas such as healthcare, biotechnology and emerging technologies.
In one of its episodes, John Oyler, Co-Founder, Chairman and CEO of BeOne Medicines, discusses the company’s journey into a global oncology company, its approach to drug development and the importance of international scientific collaboration in advancing cancer treatment.
About John Oyler
John Oyler is an American entrepreneur and pharmaceutical executive who co-founded BeOne Medicines (formerly BeiGene) in 2010. He currently serves as the company’s Chairman and CEO, leading its growth into a global biotechnology company focused on developing innovative cancer treatments.
Before founding BeOne, Oyler held leadership roles at several biotechnology companies. He holds degrees from the Massachusetts Institute of Technology and Stanford University. His work has focused on expanding cancer research, drug development and access to innovative treatments worldwide.
You may also be interested in: